Drug Profile
Methoxyamine hydrochloride - TRACON Pharmaceuticals
Alternative Names: Methoxyamine - TRACON; TRC 102Latest Information Update: 28 Sep 2023
Price :
$50
*
At a glance
- Originator Case Western Reserve University
- Developer Case Western Reserve University; National Cancer Institute (USA); TRACON Pharmaceuticals
- Class Antineoplastics; Hydroxylamines; Small molecules
- Mechanism of Action DNA repair inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Glioblastoma; Mesothelioma; Non-small cell lung cancer
- Phase I/II Solid tumours
- No development reported Haematological malignancies; Lymphoma
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, Late-stage disease) in USA (PO)
- 01 Aug 2023 National Cancer Institute (NCI) completes a phase I/II trial in Solid tumors and Lymphoma in USA (NCT01851369)
- 02 Jun 2023 Adverse events and efficacy data from a phase I trial in Solid tumours presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)